Trial · NCT06653517
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
NCT06653517, Phase 2, Recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma. Trials, record NCT06653517. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06653517
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
- NCT number
- NCT06653517
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Conditions
- Ameloblastoma, BRAF V600E Mutation Positive
- Interventions
- Dabrafenib, Trametinib
- First posted
- 2024-10-22
- Last updated
- 2024-10-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Patients Eligible for Mandibular Continuity-Preserving Surgery | After completion of two 30-day cycles of therapy (approximately 2 months) | The proportion of patients initially requiring mandibular segmental resection who become eligible for mandibular continuity-preserving surgery after preoperative targeted induction therapy with dabrafenib and trametinib. |
| Primary | Proportion of Non-radical Resectable Cases Becoming Resectable | After completion of two 30-day cycles of therapy (approximately 2 months) | The proportion of patients initially deemed non-radical resectable who become resectable after completing two cycles of preoperative targeted induction therapy with dabrafenib and trametinib. |
| Secondary | Radiological Response | After completion of two 30-day cycles of therapy (approximately 2 months) | The evaluation of tumor response using radiological studies such as MRI or CT scans after preoperative targeted induction therapy with dabrafenib and trametinib. |
| Secondary | Pathological Response | After completion of two 30-day cycles of therapy (approximately 2 months) | The assessment of tumor pathological changes after preoperative targeted induction therapy with dabrafenib and trametinib, based on biopsy or surgical specimens. |
| Secondary | Local Recurrence-Free Survival (LRFS) | 3 months | The time from the start of treatment to the occurrence of local recurrence or death from any cause, whichever occurs first. |
| Secondary | Adverse Effects and Safety | Throughout the study period, up to 12 months | The incidence and severity of adverse effects related to the combination therapy with dabrafenib and trametinib, assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06653517
GET https://conductscience.org/api/trials/v1/NCT06653517/registered